In re Diet Drugs

123 F. App'x 465
CourtCourt of Appeals for the Third Circuit
DecidedJanuary 25, 2005
DocketNos. 04-3591, 04-3643, 04-4096
StatusPublished

This text of 123 F. App'x 465 (In re Diet Drugs) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Diet Drugs, 123 F. App'x 465 (3d Cir. 2005).

Opinion

OPINION

WEIS, Circuit Judge.

The underlying issues here involve claims of personal injury caused by the use [467]*467of two appetite suppressant drugs produced and distributed by Wyeth. We provided a lengthy summary of the facts in our opinions at 369 F.3d 293 (3d Cir.2004) and 282 F.3d 220 (3d Cir.2002). Consequently, we will limit our restatement of the background here.

I.

In the mid-1990s, data surfaced suggesting a link between use of the Wyeth diet drugs and valvular heart disease (VHD) in humans. As a result, thousands of lawsuits were filed against Wyeth in state and federal courts. The Judicial Panel for Multidistrict Litigation transferred all the federal actions to the United States District Court for the Eastern District of Pennsylvania.

In 1999, the parties reached a tentative settlement agreement for a nationwide class. In exchange for Wyeth’s payment of $3.75 billion, the agreement provided that settling class members would release Wyeth from all VHD claims. After conducting a fairness hearing, the District Court entered a final order certifying the class and approving the settlement on August 28, 2000. The terms of the settlement agreement and the final order indicated that the District Court shall have continuing jurisdiction to administer, interpret and enforce the settlement agreement.

Class members were entitled to opt out of the settlement agreement initially, at an intermediate stage or at the “back-end.” Those who decided to opt-out at the intermediate stage were informed that the scope of their claims would be limited and specifically they were precluded from “seeking” punitive, exemplary, or multiple damages. The settlement agreement reads,

“[Intermediate opt-outs] may not seek punitive, exemplary, or any multiple damages against [Wyeth]; .... [Intermediate opt-outs] may not use any previous verdicts or judgments against [Wyeth], or factual findings necessary to such verdicts or judgments, for purposes of establishing claims or facts in order to obtain a verdict or judgment.... Nor may [an intermediate opt-out] ... seek to introduce into evidence against [Wyeth], for any purpose, such a verdict, judgment or factual finding.”

In return for these limitations, Wyeth agreed not to assert any statute of limitations, laches, or similar defenses against the intermediate opt-outs.

In state courts, most of the opt-out plaintiffs pleaded their claims in terms that appeared to abide by the prohibition on seeking punitive damages. However, tactics employed during litigation demonstrated that some plaintiffs were attempting to obtain punitive-type damages through such means as inflated mental anguish recovery and by presenting evidence of reprehensible conduct by Wyeth.

A. Initial Injunctions

In response to the attempted circumvention of the punitive damages bar, the District Court issued PTO 2625 in plaintiff Clara Clark’s case as well as a similar pretrial order, PTO 2828, applicable to other plaintiffs. In addition, the court issued PTO 3088 enjoining plaintiffs from making arguments related to punitive damages and malicious or wanton conduct by Wyeth, as well as prohibiting them from introducing specific categories of evidence and identified exhibits.

B. Initial Appeal

Plaintiffs appealed, contending that the injunctions did not comply with the settlement agreement or notions of federalism. [468]*468On May 25, 2004, we vacated PTO 2828 and remanded with instructions to the District .Court to modify its pre-trial orders.1 In re Diet Drugs, 369 F.3d at 317-19. We concluded that the District Court had the power, under the All Writs Act, to effectuate and protect the terms of the settlement through pretrial injunctions affecting state court proceedings. However, we cautioned that opt-outs must be able to fairly litigate the claims preserved under the agreement, and that “intrusion into state court proceedings should be minimized.” Id. at 317.

We noted that PTO 2828 was appropriate in so far as it prohibited the parties from:

(i) introducing any evidence relevant “exclusively” to punitive damages, specifically evidence of Wyeth’s:
(a) profits, size or financial condition, and
(b) amount or size of sales of diet drugs or other products; and
(ii) making “ ‘any statement or argument to the ... jury related directly to evidence relevant only to punitive damages.’ ”

Id.

In addition to specifically approving portions of PTO 2828, we required that the following provisions be excised:

(i) categorical evidentiary restrictions that barred evidence relevant to proving VHD claims;
(ii) limitations on exhibits and deposition testimony that precluded evidence relevant to VHD claims; and (in) prohibitions on “making any statement or argument to the court” on matters other than those specified.

Id. at 317-18.

Finally, in addition to the required revisions and specifically approved provisions, we suggested that the District Court consider other measures aside from imposing evidentiary restraints,

“for example, ordering language to be included in a stipulation or proposed jury instruction that would make it clear to the jury that exemplary damages may not be awarded. Or ... directing] the parties to agree to a bifurcated trial-where damages are determined apart from liability-in the event that the state court were to deem it advisable.”

Id. at 318.

C. PTO 3888 and District Court Actions Thereafter

In response to our May 2004 opinion and after hearing argument from the parties, the District Court issued PTO 38882 which reads as follows:

“AND NOW, on this 30th day of August, 2004, for the reasons set forth in the accompanying Memorandum, it is hereby ORDERED that”:
(1) Pretrial Orders (“PTO”) Nos. 2680, 2828, 2883, 3088, and 3123 are VACATED;

[469]*469(2) plaintiffs, their agents, attorneys, and derivative claimants are ENJOINED from introducing any evidence, or making any statements before or argument to [the] jury related to:

(a) punitive, exemplary, or multiple damages;
(b) Wyeth’s profits, size, or financial condition; or
(c) the amount or size of Wyeth’s sales of diet drugs or other products;

in the following cases: Smart v. American Home Prods., Inc., No. 02-04-40259-CV (Jim Wells County, Tex.) (PTO No. 2680); Clark v. Wyeth, et al., No. B020282-C (Orange County, Tex.) (PTO No. 2828); Wilson, et al. v. Wyeth, et al, No. 03cv305BN (S.D. Miss.), and James, et al. v. Wyeth, et al., No.2002-95 (Smith County, Miss.) (PTO No. 2883); Eichmiller v. American Home Products Corp., Civil Action No.2002CV52077 (Fulton County, Georgia), Cook, et al. v. Wyeth,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Chambers Development Company, Inc.
148 F.3d 214 (Third Circuit, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
123 F. App'x 465, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-diet-drugs-ca3-2005.